<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476735/" ref="ordinalpos=2102&amp;ncbi_uid=4306812&amp;link_uid=PMC3476735" image-link="/pmc/articles/PMC3476735/figure/F5/" class="imagepopup">Figure 5. Flow diagram showing the molecular mechanism of metformin-mediated reduction in SCC growth.  From: Metformin, an anti-diabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody">Metformin targets multiple signaling pathways to reduce the growth of cutaneous SCCs in a xenograft murine model system. The major pathways blocked by metformin treatment include mTOR, NFkB, Akt and MAP kinases. Metformin activates AMPK which blocks mTOR signaling while inhibition in NFkB pathway reduces proliferation via blocking activation of genes involved in cell cycle progression and enhancing genes that augment apoptosis.</div></div>